<iframe src="//www.googletagmanager.com/ns.html?id=GTM-K799DP4&l=dataLayer" height="0" width="0" style="display:none;visibility:hidden"></iframe>
NAS:CDNA (USA) Also Trade In: Germany

CareDx Inc $ 26.17 -0.15 (-0.57%)

Volume:
753,331
Avg Vol (1m):
869,371
Market Cap $:
1.11 Bil
Enterprise Value $:
1.07 Bil
P/E (TTM):
0.00
P/B:
11.82
Warning! GuruFocus has detected 3 Severe warning signs with CDNA. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 1Y (-%)

CDNA News and Headlines - CareDx

GuruFocus Articles Total 80
  • 1
  • 2
  • 3
  • 4

BRISBANE, Calif., Oct. 17, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. ( CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it will release financial results for the third quarter 2019 after the market closes on Thursday, October 31st, 2019. Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financial Officer, will host a conference call to review the Company’s results beginning at 1:30pm PT/4:30pm ET.

Individuals interested in listening

0 Views    Marketwired    2019-10-17 16:01

CareDx joins UI Health and NKF to meet with Senator Durbin and advocate for action on anti-rejection drug coverage for kidney transplant patients

BRISBANE, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. ( CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, recently participated in a roundtable meeting with U.S. Senator Richard Durbin (D-IL) to discuss his efforts in Congress to expand immunosuppressive medication coverage for kidney transplant recipients.

0 Views    Marketwired    2019-10-08 16:02

CareDx protects transplantation innovation by enforcing patent protection

BRISBANE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. ( CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has filed a patent infringement suit against Eurofins Viracor, Inc., in the United States District Court for Delaware.  CareDx is asserting U.S. Patent No. 8,703,652, which is exclusively licensed to CareDx from Stanford University.  This patent covers non-invasive monitoring

0 Views    Marketwired    2019-09-26 16:00

CareDx partners with NanoString to improve precision of transplant biopsies

BRISBANE, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. ( CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced a strategic partnership with NanoString to develop HistoMap, a gene expression profiling (GEP) solution to identify allograft rejection in transplant biopsy tissue.

Seattle-based NanoString ( NSTG) is a leading provider of life science tools for translational research

0 Views    Marketwired    2019-09-24 16:01

Artificial Intelligence algorithm predicts long-term kidney transplant outcomes

BRISBANE, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. ( CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announces that the iBox validation study from the Paris Transplant Group has been published in the British Medical Journal (BMJ).

CareDx launched KidneyCare at the American Transplant Congress in June 2019. KidneyCare includes the iBox technology as a prognostic measurement alongside

0 Views    Marketwired    2019-09-23 16:01

AlloSeq Tx 17 is a best in class HLA typing solution with the most comprehensive sequencing and easiest workflow

BRISBANE, Calif., Sept. 20, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. ( CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, will launch AlloSeq Tx 17 during the American Society for Histocompatibility and Immunogenetics (ASHI) and Banff Foundation for Allograft Pathology’s Joint meeting in Pittsburgh, PA from September 23-27, 2019.

AlloSeq Tx

0 Views    Marketwired    2019-09-20 16:00

CareDx drives best in class 4,000 transplant patient registry with KOAR and OKRA

BRISBANE, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. ( CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the enrollment of the first patient in the Outcomes of KidneyCare in Renal Allografts (OKRA) registry from the University of Maryland School of Medicine.

OKRA is a multicenter, prospective, observational registry, designed to

0 Views    Marketwired    2019-09-18 16:00

BRISBANE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. ( CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financial Officer, will be participating in the Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 2nd at 2:25 PM ET. 

A live audio webcast of the Cantor Fitzgerald Global Healthcare Conference presentation will be available online from the investor relations

0 Views    Marketwired    2019-09-17 16:00

CareDx will establish access to dd-cfDNA surveillance solutions for transplant patients worldwide

BRISBANE, Calif., Sept. 12, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. ( CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, will launch its new kit-based donor derived cell free DNA (dd cfDNA) surveillance test AlloSeq cfDNA during the European Society for Organ Transplantation (ESOT) Congress.

AlloSeq cfDNA has been utilized by beta sites in 4 countries, and

0 Views    Marketwired    2019-09-12 16:00

BRISBANE, Calif., Sept. 11, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. ( CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that, as an inducement material to entering into employment with CareDx, on September 11, 2019, 53 new employees were awarded grants of stock options and restricted stock units (RSUs). The stock options and RSUs were granted pursuant to the Company’s 2019 Inducement Equity Incentive Plan, which was approved by the Compensation

0 Views    Marketwired    2019-09-12 00:00

Acquisition solidifies transplant leadership with transplant center quality management and patient waitlist management tools

BRISBANE, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. ( CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has completed the acquisition of XynManagement, the leading provider of solutions to simplify transplant quality tracking and waitlist management. Financial details of the transaction were not disclosed.

XynManagement provides two unique solutions,

0 Views    Marketwired    2019-08-28 16:00

Cournoyer brings deep digital expertise to CareDx to support burgeoning digital solutions portfolio

BRISBANE, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. ( CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that Chris Cournoyer is joining the CareDx Board of Directors.

Cournoyer was previously the Chairperson and Chief Executive Officer for N-of-One. N-of-One is a leader in precision medicine delivering clinical and molecular decision

0 Views    Marketwired    2019-08-27 16:00

CareDx expands leadership with cfDNA for transplant care

BRISBANE, Calif., Aug. 22, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. ( CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announces AlloSure received a positive draft Local Coverage Determination (dLCD) for Medicare coverage in heart transplant patients.

The Centers for Medicare and Medicaid Services (CMS) released the draft version of the coverage policy issued by Palmetto GBA, the Medicare administrator

0 Views    Marketwired    2019-08-22 16:00

CareDx partnership with American Association of Kidney Patients yields key patient insights

BRISBANE, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. ( CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced results of a national informational survey conducted with The American Association of Kidney Patients (AAKP) of kidney transplant recipients that assessed their key concerns about monitoring kidney health post-transplant.

A total of 170 adults

0 Views    Marketwired    2019-08-21 16:00

NEW YORK, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against CareDx, Inc. ( CDNA) on behalf of CareDx investors. Our investigation concerns whether CareDx has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On July 16, 2019, Kerrisdale Capital Research released a report alleging, among other things, that the Company’s diagnostic test, AlloSure, is “fundamentally incapable of identifying the most common type of kidney

0 Views    Marketwired    2019-08-06 04:00

NEW YORK, July 30, 2019 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of CareDx Inc. (“CareDx” or the “Company”) ( CDNA) resulting from allegations that CareDx and/or its executives may have issued materially misleading information to the investing public.

If you purchased CareDx securities, and/or would like to discuss your legal rights and options please visit CareDx CDNA Shareholder Investigation or contact Matthew E. Guarnero

0 Views    Marketwired    2019-07-30 20:01

NEW YORK, July 30, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against CareDx, Inc. (“CareDx” or the “Company”) (CDNA).

If you invested in CareDx stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/CDNAThere is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected] 

CONTACT:
FARUQI &

0 Views    Marketwired    2019-07-30 16:02

PR Newswire

NEW YORK, July 26, 2019 /PRNewswire/ --  

Amneal Pharmaceuticals, Inc. (AMRX)

Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that Amneal was involved in anticompetitive practices.

If you are an AMRX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

CareDx, Inc. (CDNA)

0 Views    PRNewswire    2019-07-27 00:03

PR Newswire

NEW YORK, July 24, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against CareDx, Inc. ("CareDx" or the "Company") (NASDAQ:CDNA).

Faruqi & Faruqi, LLP. (PRNewsfoto/Faruqi & Faruqi, LLP)

If you invested in CareDx stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/CDNAThere is

0 Views    PRNewswire    2019-07-25 00:09

NEW YORK, July 23, 2019 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of CareDx Inc. (“CareDx” or the “Company”) ( CDNA) resulting from allegations that CareDx and/or its executives may have issued materially misleading information to the investing public.

If you purchased CareDx securities, and/or would like to discuss your legal rights and options please visit CareDx CDNA Shareholder Investigation or contact Matthew E. Guarnero

0 Views    Marketwired    2019-07-23 20:03

Headlines Total 126
  • 1
  • 2

2019-10-18 $ 26.17 (-0.57%)
9:09am
2019-10-17 $ 26.32 (1.08%)
11:01am
2019-10-08 $ 26.07 (-0.11%)
11:02am
2019-10-07 $ 26.1 (2.88%)
9:20am
2019-09-26 $ 21.71 (-4.36%)
11:00am
2019-09-24 $ 22.09 (-5.6%)
11:01am
2019-09-23 $ 23.4 (-2.74%)
11:01am
2019-09-20 $ 24.06 (-0.33%)
11:00am
2019-09-18 $ 23.87 (1.75%)
11:00am
2019-09-17 $ 23.46 (-0.89%)
11:00am
2019-09-12 $ 21.96 (7.44%)
11:00am
2019-09-11 $ 20.44 (2.05%)
7:00pm
2019-09-06 $ 21.7 (-5.28%)
4:27pm
2019-08-28 $ 23.86 (2.84%)
11:00am
2019-08-27 $ 23.2 (-0.64%)
11:00am
2019-08-22 $ 23.62 (-0.51%)
11:00am
2019-08-21 $ 23.74 (-3.61%)
11:00am
2019-08-05 $ 30.67 (-12.4%)
11:00pm
2019-08-02 $ 35.01 (2.97%)
8:59pm
2019-07-30 $ 34.25 (3.57%)
3:01pm
11:02am
2019-07-25 $ 31.29 (-5.12%)
9:34am
2019-07-23 $ 32.7 (-0.97%)
3:03pm
2019-07-16 $ 32.57 (-12.91%)
4:09pm
11:01am
10:00am
2019-07-11 $ 40.08 (1.39%)
11:03am
2019-07-10 $ 39.53 (2.46%)
4:32pm
2019-07-02 $ 35.71 (-0.45%)
11:08am
2019-06-27 $ 35.97 (3.72%)
11:01am
2019-06-26 $ 34.68 (-2.61%)
11:01am
2019-06-10 $ 36.36 (-2.75%)
11:00am
2019-05-29 $ 31.07 (-2.23%)
11:02am
2019-05-22 $ 33.21 (-2.29%)
11:02am
2019-05-14 $ 33.4 (3.63%)
11:03am
2019-05-09 $ 32.9 (12.86%)
12:14pm
2019-05-08 $ 29.15 (1.85%)
10:44pm
9:48pm
5:45pm
2019-05-07 $ 28.62 (-5.95%)
11:01am
2019-05-03 $ 30.06 (5.92%)
11:00am
2019-05-02 $ 28.38 (4.88%)
7:01am
2019-05-01 $ 27.06 (-0.55%)
9:33am
2019-04-30 $ 27.21 (-1.45%)
5:58pm
2019-04-25 $ 25.95 (-1.93%)
7:02pm
2019-04-23 $ 26.65 (3.37%)
7:01am
2019-04-10 $ 29.61 (4.89%)
11:02am
2019-04-03 $ 32.18 (1.8%)
7:00am
2019-03-26 $ 36.9 (-0.99%)
11:01am
2019-03-13 $ 36.86 (1.96%)
7:02am
2019-03-11 $ 34.8 (1.87%)
11:04am
2019-03-08 $ 34.16 (0.65%)
7:58am
2019-03-07 $ 33.94 (9.84%)
3:46pm
2019-03-06 $ 30.9 (-2.15%)
9:15pm
8:04pm
2019-03-05 $ 31.58 (0.32%)
11:05am
2019-02-26 $ 29 (-1.73%)
11:07am
2019-02-21 $ 28.04 (4.35%)
11:00am
2019-02-20 $ 26.87 (2.17%)
11:16am
2019-02-19 $ 26.3 (-0.79%)
7:26pm
2019-02-14 $ 23.99 (1.87%)
11:05am
2019-02-06 $ 25.23 (-2.13%)
11:03am
2019-01-09 $ 27.31 (3.41%)
7:02am
2019-01-07 $ 25.5 (2.33%)
3:20pm
7:04am
2019-01-03 $ 22.61 (-5.71%)
7:35am
2019-01-02 $ 23.98 (-4.61%)
10:10am
2018-12-20 $ 22.95 (-9.43%)
7:02am
2018-12-17 $ 24.38 (-11.15%)
7:01pm
2018-11-26 $ 27.72 (3.05%)
7:00pm
11:02am
2018-11-16 $ 29.95 (0.81%)
7:00pm
2018-11-13 $ 25.49 (-7.41%)
11:00pm
7:00pm
2018-11-10
5:10am
2018-11-08 $ 27.74 (-2.26%)
5:20pm
2018-11-07 $ 28.38 (3.16%)
11:01am
3:12am
2018-11-06 $ 27.51 (3.46%)
8:39am
2018-11-01 $ 27.28 (4.48%)
10:28am
2018-10-29 $ 23.92 (-0.91%)
3:53pm
2018-10-17 $ 25.48 (6.88%)
7:01am
2018-10-09 $ 23.92 (-1.12%)
1:12pm
2018-10-02 $ 25.73 (-7.91%)
11:04am
2018-09-27 $ 27.46 (-4.35%)
10:08am
2018-09-21 $ 25.95 (0.35%)
11:03am
2018-09-18 $ 27.14 (4.22%)
7:58am
2018-09-17 $ 26.04 (-0.46%)
11:04am
2018-08-24 $ 21.2 (4.43%)
6:11am
2018-08-15 $ 16.86 (-0.12%)
11:01am
2018-08-13 $ 16.95 (-0.24%)
8:15am
2018-08-12
7:03pm
2018-08-09 $ 14.97 (1.63%)
5:00pm
2018-07-17 $ 12.55 (2.7%)
9:11pm
2018-07-16 $ 12.22 (-1.37%)
7:00am
2018-06-28 $ 12.62 (5.08%)
11:02am
2018-06-19 $ 15.6 (-1.14%)
11:03am
2018-06-05 $ 14.96 (11.56%)
11:07am
2018-06-01 $ 13.44 (1.51%)
11:01am
2018-05-09 $ 11.2 (4.38%)
11:02am
Total 126
  • 1
  • 2